ThromboGenics' JETREA receives reimbursement in Spain
ThromboGenics announces that the Spanish Ministry of Health has approved the reimbursement of JETREAź (ocriplasmin) for the treatment of adults with vitreomacular traction, including when associated with macular hole of diameter less than or equal to 400 microns. September 01, 2014